Drug Device Combination Products Market: Growth, Size, Share, and Trends

Report Code MD 9361
Published in May, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Drug Device Combination Products Market by Type (Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application (Diabetes, Oncology, Pain, Opthamology), End User (Hospital, Home Care), and Region - Global Forecast to 2030

Overview

The global drug device combination products market, valued at US$224.70 billion in 2024, stood at US$243.02 billion in 2025 and is projected to advance at a resilient CAGR of 9.3% from 2025 to 2030, culminating in a forecasted valuation of US$379.17 billion by the end of the period. The increasing prevalence of chronic diseases worldwide, coupled with the introduction and approval of innovative advanced therapeutics, is driving significant market expansion. The trend towards advanced drug-device combination products is gaining momentum, influenced by the rising demand for self-administration solutions in home healthcare environments. This shift toward home-based care is largely attributed to the aging population, which has led to a larger demographic of patients managing conditions such as diabetes, obesity, and cancer. Furthermore, favorable reimbursement policies and enhanced healthcare infrastructure are facilitating improved access to these combination products. As a result, sustained growth is anticipated in this market segment over the forthcoming years.

Drug Device Combination Products Market– Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Drug Device Combination Products Market

North America

Market growth in North America can be attributed to rising patient pool with chronic diseases such as diabetes, obesity, large presence of potential companies.

The growth of this market can be attributed to the increasing prevalence of chronic diseases, technological advancements, new product launches, and an emphasis on patient compliance.

Increased preference of self administration and home care, rising focus on patient centric design and connected device, and growing opportunities in emerging economies are likely to promote significant growth opportunity of the market

North America dominates the drug device combination products market; this market is projected to reach USD 175.26 billion by 2030, at a CAGR of 8.5% during the forecast period.

North America is the largest regional market for drug device combination products, and the US dominates the North American market.

Global Drug Device Combination Products Market Dynamics

DRIVER: Rising prevalence of chronic diseases

The increasing incidence of chronic diseases is anticipated to escalate the demand for drug-device combination products. Contributing factors include an aging demographic and lifestyle influences such as poor nutrition, obesity, and sedentary behavior. According to projections from the International Diabetes Federation (IDF, 2025), the population of adults living with diabetes is expected to rise from 588.7 million to 853 million by 2050. In 2024 alone, diabetes was responsible for approximately 3.4 million deaths and incurred an estimated global healthcare expenditure of USD 1.015 trillion. Another significant factor driving this trend is the obesity epidemic. The World Health Organization (WHO, 2024) reports that over 1 billion individuals are classified as obese, comprising 650 million adults, 340 million adolescents, and 39 million children. By 2025, it is projected that around 167 million people will encounter health complications attributable to overweight or obesity. This condition is associated with a range of chronic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnea. As the prevalence of these chronic conditions rises, so too does the need for sophisticated drug delivery systems. Drug-device combination products—such as insulin pens, autoinjectors, inhalers, and wearable drug delivery systems—are becoming pivotal in managing these diseases effectively. These advanced technologies facilitate improved patient adherence, targeted drug administration, and enhanced therapeutic outcomes. Consequently, the market for drug-device combination products is poised for substantial growth in the coming years.

RESTRAINT: Stringent regulatory requirements

Stringent regulatory frameworks pose significant challenges to the development and innovation of drug-device combination products (DDCPs), adversely impacting market growth due to heightened compliance requirements, protracted approval timelines, and increased financial risk. Regulatory bodies, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose complex and often overlapping demands on these products, necessitating adherence to both pharmaceutical and medical device regulations. This dual regulatory pathway complicates the development process and can extend commercialization timelines. For example, the FDA's Office of Combination Products (OCP) is tasked with determining the principal classification of DDCPs—whether they are primarily categorized as a drug, device, or biologic—thereby dictating the applicable regulatory pathway, whether it be Premarket Approval (PMA) for devices or New Drug Application (NDA) for drugs. The FDA’s 2023 Annual Report indicates that nearly 30% of submissions encounter delays due to classification disputes, resulting in a timeframe of 12 to 18 months before mitigated policies can be implemented (Deloitte, 2022). The situation is further exacerbated by the absence of global regulatory harmonization. As manufacturers prepare for evolving—or, in some cases, divergent—standards from various jurisdictions such as the EU’s Medical Device Regulation (MDR), the National Medical Products Administration (NMPA) in China, and the Central Drugs Standard Control Organization (CDSCO) in India, the regulatory landscape becomes increasingly convoluted. According to McKinsey (2023), approximately 30–40% of industry respondents report encountering significant challenges in aligning submissions across different markets. Consequently, stringent regulatory requirements continue to serve as a fundamental barrier to innovation and prompt patient access to drug-device combination products.

 

OPPORTUNITY: High growth opportunities in emerging markets

The emerging economies of China, India, and Brazil present significant growth opportunities for manufacturers in the drug-device combination products sector. In China and India, there is a notable uptick in investment in medical technology driven by escalating healthcare costs and the rising demand for advanced medical solutions. The aging population in China, coupled with a growing need for sophisticated chronic disease management, is catalyzing the development of integrated approaches, particularly drug-device combination products. These countries, identified as high-potential markets, are witnessing a substantial increase in healthcare expenditure as a direct result of heightened demand for healthcare infrastructure and a deepening awareness of chronic disease management. In India, the surge in spending reflects a broader commitment to improving disease management strategies, fostering a lucrative market for innovative combination products that aim to enhance treatment efficacy through precision drug delivery. Looking ahead, the next few years are expected to bring considerable infrastructural advancements in healthcare facilities, supported by increased budgets. Moreover, emerging economies in the Asia Pacific region are poised to maintain a competitive edge, largely attributable to lower production costs. This landscape creates a compelling incentive for market players to pursue investments in these regions, thereby potentially accelerating the development and distribution of cutting-edge healthcare solutions.

CHALLENGES: Product malfunction and wastage of drugs

Drug-device combination products face significant challenges related to product malfunctions and waste, which impact healthcare costs, patient safety, and treatment efficacy. According to BD's whitepaper titled "The Value of an Integration System for Combination Products," these issues often stem from inadequate integration of drug and device components, design flaws, and usability errors. A notable concern is the wastage of pharmaceuticals, with devices such as prefilled syringes and autoinjectors frequently leading to incomplete administration, leakage, or blockages, ultimately causing under-dosing. BD's research indicates that 5% to 10% of the drug volume may be lost during these processes. This necessitates healthcare providers to use additional supplies, escalating costs and increasing contamination risks. Mechanical failures, such as autoinjector clogs or needle retraction failures, as well as unreliable drug delivery mechanisms (e.g., inconsistent performance of stents or inhalers), further compound these challenges. User errors, particularly among elderly or inexperienced patients, also heighten the risk of device malfunction. Financially, manufacturers may face substantial expenses related to recalls, replacements, and liability claims, potentially reaching millions. Concurrently, hospitals bear the burden of increased procurement costs and waste management issues. Regulatory bodies, including the FDA, impose stricter oversight on malfunctioning drug-device combination products, which can prolong approval timelines. To mitigate these challenges, it is essential for manufacturers to focus on enhanced design, improved integration, and comprehensive user training. This approach is critical to ensuring reliability, safeguarding patient safety, and achieving business viability.

Global Drug Device Combination Products Market Ecosystem Analysis

Drug-device combination products span both the pharmaceutical and medical technology sectors, involving the collaboration of pharmaceutical companies, medical device manufacturers (MDMs), contract development organizations (CDOs), and regulatory bodies. These products combine a drug and a device, which means their design and functionality must work seamlessly together. Regulatory agencies, such as the FDA and EMA, enforce dual control, making the approval process more complex. End users include patients, healthcare providers, and caregivers who depend on these products for effective treatment. Hospitals and pharmacies also play a critical role in ensuring accessibility and the proper use of these combination products.

Drug Device Combination Products Market
 

Injectable drug delivery devices held the largest market share in 2024

The injectable drug delivery devices segment is the largest growing category within the drug-device combination products market. This growth is primarily attributable to the precision, rapid response, and targeted drug delivery capabilities of injectables, which are particularly essential for advanced biologics and therapies that exhibit instability or reduced efficacy when administered orally. Devices such as autoinjectors, prefilled syringes, and pen injectors are gaining traction due to their user-friendliness, portability, and minimal need for clinical administration. The rising prevalence of chronic conditions, including cancer, rheumatoid arthritis, and diabetes, is significantly propelling the demand for injectable combination products. Self-administration devices enhance patient convenience, thereby alleviating pressure on healthcare systems. Innovations such as needle safety features, dose accuracy mechanisms, and connected (smart) injectors are improving adherence, reducing user errors, and overall enriching the patient experience. Moreover, the demand for efficient drug delivery systems is intensifying in response to an aging global population and the proliferation of biological therapies. Support from regulatory bodies advocating for patient-centric designs and the growing trend toward home-based care models are further accelerating the momentum of the injectable drug-device combination product market. Consequently, these devices are set to play a vital role in the evolving landscape of personalized and effective healthcare delivery.

Home care settings will grow at the highest CAGR during the study period.

The drug-device combination products market is segmented based on end-users into hospitals and clinics, ambulatory surgery centers, long-term care facilities, home care settings, and other end users. The home care segment is experiencing robust growth, driven by patients with chronic conditions such as diabetes, asthma, and cancer opting for home self-administration to optimize time management and reduce healthcare costs associated with frequent hospital visits. Recent innovations in this space include user-friendly, portable, and connected devices such as autoinjectors, insulin delivery wearables, and smart inhalers, which facilitate effective home-based treatment. Additionally, an aging population, alongside increasing healthcare burdens on institutional settings, has heightened the demand for personalized and patient-centered healthcare solutions. Factors such as improved patient comfort, enhanced compliance with therapeutic regimens, and overall quality of life further bolster the appeal of home-based therapies. As a result, home care emerges as a pivotal and expanding segment within the drug-device combination products market.

North America accounted for the largest market share in 2024.

North America is projected to dominate the market for drug-device combination products over the forecast period. This anticipated growth can be attributed to several key factors, including favorable reimbursement frameworks, heightened public awareness surrounding innovative technologies, and supportive government policies. Additionally, the increased affordability and per capita healthcare spending have further strengthened the market landscape. Companies such as Abbott, Becton Dickinson and Company, and Eli Lilly and Company, all based in the US, foster robust research environments that promote continuous innovation in drug-device combinations. The emphasis on R&D leads to the development of a diverse array of effective solutions, appealing to both healthcare providers and patients. Moreover, North America's well-established healthcare infrastructure facilitates access to advanced medical technologies, ensuring timely deployment and adoption of innovative products. Concomitantly, the aging population in these regions is likely to face a higher prevalence of chronic conditions, subsequently escalating the demand for effective drug-device combination therapies. This interplay of factors solidifies a sustained demand for drug-device combination products throughout the region.

LARGEST Share (2024)
US FASTEST-GROWING MARKET IN THE REGION
Drug Device Combination Products Market

Recent Developments of Drug Device Combination Products Market

  • In March 2025, Terumo Europe received MDR approval for an expanded indication of its Ultimaster Nagomi and Ultimaster Tansei sirolimus-eluting coronary stent systems. This new approval covers patients at high bleeding risk, including those eligible for dual antiplatelet therapy (DAPT) for as short as one month.
  • In January 2025, Eli Lilly and Company received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
  • In July 2024, AbbVie received European Commission approval for SKYRIZI (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC)
  • In May 2024, Abbott launched the XIENCE Sierra Everolimus-Eluting Coronary Stent System in India. As the latest in the XIENCE family, it offers advanced safety and effectiveness for treating blocked coronary arteries, particularly in complex cases.

Key Market Players

KEY PLAYERS IN THE DRUG DEVICE COMBINATION PRODUCTS MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Drug Device Combination Products Market?

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD Million/Billion) 
Segments covered Product Type, Application, End User
Geographies covered North America (US and Canada), Europe (Germany, UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, Australia, South Korea, India, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries {UAE, Saudi Arabia, and Rest of GCC countries}, and Rest of Middle East & Africa)

Frequently Asked Questions (FAQ)

What are the drivers for the drug device combination products market?

The increasing incidence of chronic diseases like diabetes, a favorable reimbursement climate, and a focus on developing technologically advanced drug-device combination products are expected to drive market growth during the forecast period.

Which therapy segment in the drug device combination products market provides the most opportunity for growth?

The diabetes segment offers the most growth opportunity due to rising diabetes prevalence, an aging population, government initiatives, and increased patient awareness. This drives demand for insulin and GLP-1 drug-device combination products.

Which end-user segment is expected to show strong growth?

The home care setting segment is expected to grow significantly, driven by an aging population, technological advancements, patient preference for self-administration, cost-effectiveness, favorable reimbursement, and government support.

What are the main vendors present in this sector?

Key vendors include Abbott (US), Boston Scientific Corporation (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), and AbbVie Inc. (US).

Which region is expected to witness significant demand for the drug device combination products market in the coming years?

The Asia Pacific region, especially China and India, is expected to see significant demand due to rising chronic disease prevalence, improved healthcare infrastructure, increased awareness of diabetes care, and advancements in self-administered combination products.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Drug Device Combination Products Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
29
RESEARCH METHODOLOGY
33
EXECUTIVE SUMMARY
46
PREMIUM INSIGHTS
51
MARKET OVERVIEW
54
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising prevalence of chronic diseases
    - Growing adoption of biologics and vaccines
    - High R&D investments from government organizations and private bodies
    - Shift toward personalized medicines and patient-centric care
    - Rising popularity of self-administered medicines
    RESTRAINTS
    - Stringent regulatory policies and compliance hurdles
    - Focus on alternative drug delivery methods
    OPPORTUNITIES
    - Increased preference for minimally invasive products
    - High growth potential in emerging economies
    - Growing adoption of drug device combination products and expanding biologics market
    CHALLENGES
    - Heavy financial impact of drug wastage and device malfunction
    - Lack of standardized reimbursement policies
    - Limited training and education for healthcare professionals
    - Lack of medical specialists and surgeons
  • 5.3 INDUSTRY TRENDS
    RISING POPULARITY OF SELF-ADMINISTERED MEDICINES AND HOME CARE SETTINGS
    INTEGRATION OF DRUG DEVICE COMBINATION PRODUCTS WITH SMART CONNECTED DEVICES
  • 5.4 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Wearable technologies
    - Drug-eluting technologies
    COMPLEMENTARY TECHNOLOGIES
    - Connected health and digital technologies
    ADJACENT TECHNOLOGIES
    - Advanced materials and biopolymers
  • 5.5 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.7 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
  • 5.8 PATENT ANALYSIS
    KEY PATENTS GRANTED
  • 5.9 TRADE ANALYSIS
    TRADE ANALYSIS FOR PREFILLED SYRINGES (HS CODE 300431), 2019–2023
    - Import data for HS Code 300431
    - Export data for HS Code 300431
    TRADE DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), 2019–2023
    - Import data for HS Code 300431
    - Export data for HS Code 300431
  • 5.10 PRICING ANALYSIS
    INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024
    AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY DEVICES, BY KEY PLAYER, 2022–2024
    AVERAGE SELLING PRICE TREND OF DRUG DELIVERY COMBINATION PRODUCTS, BY REGION, 2022–2024
    - Average selling price trend for pen injectors, 2022–2024
    - Average selling price trend for inhalers, 2022–2024
    - Average selling price trend for drug-eluting stents, 2022–2024
  • 5.11 VALUE CHAIN ANALYSIS
  • 5.12 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.13 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.14 ADJACENT MARKET ANALYSIS
  • 5.15 ECOSYSTEM ANALYSIS
    ROLE IN ECOSYSTEM
  • 5.16 CASE STUDY ANALYSIS
    MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY
    DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION
    ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES
  • 5.17 SUPPLY CHAIN ANALYSIS
  • 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.19 INVESTMENT & FUNDING SCENARIO
  • 5.20 REIMBURSEMENT SCENARIO ANALYSIS
  • 5.21 CLINICAL PIPELINE ANALYSIS
  • 5.22 IMPACT OF AI/GEN AI ON DRUG DEVICE COMBINATION PRODUCTS MARKET
  • 5.23 IMPACT OF 2025 US TARIFF ON DRUG DEVICE COMBINATION PRODUCTS MARKET
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRY/REGION
    - North America
    - Europe
    - Asia Pacific
    IMPACT ON END-USE INDUSTRIES
    - Hospitals & clinics
    - Ambulatory surgery centers
    - Long-term care facilities
    - Home care settings
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE
108
  • 6.1 INTRODUCTION
  • 6.2 INJECTABLE DRUG DELIVERY DEVICES
    PREFILLED SYRINGES
    - Need to eliminate dosing mistakes and improve patient compliance to drive segment
    PEN INJECTORS
    - Ease of self-administration and improved dosage accuracy to fuel adoption
    AUTOINJECTORS
    - Ease of use and better patient experience to aid adoption in emergency medical conditions
    WEARABLE INJECTORS
    - Rising popularity of embedded wireless devices to propel market growth
    NEEDLE-FREE INJECTORS
    - Reduced risk of needlestick injury to fuel market adoption
  • 6.3 DRUG-ELUTING STENTS
    LOW RATE OF RESTENOSIS TO PROPEL MARKET GROWTH
  • 6.4 INHALERS
    INCREASING PREVALENCE OF RESPIRATORY DISEASES TO FUEL UPTAKE
  • 6.5 INFUSION PUMPS
    RISING NUMBER OF SURGICAL PROCEDURES TO FUEL DEMAND FOR AMBULATORY INFUSION PUMPS
  • 6.6 TRANSDERMAL PATCHES
    RISING INCIDENCE OF CHRONIC DISEASES REQUIRING LONG-TERM MEDICATION TO AID MARKET GROWTH
  • 6.7 DRUG-COATED BALLOONS
    ABILITY TO DELIVER LOCALIZED DRUG THERAPY WITH MINIMAL SYSTEMIC EXPOSURE TO DRIVE MARKET
  • 6.8 OTHER PRODUCT TYPES
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION
133
  • 7.1 INTRODUCTION
  • 7.2 DIABETES MANAGEMENT
    HIGH GERIATRIC POPULATION AND INCREASED SEDENTARY LIFESTYLE TO PROPEL MARKET GROWTH
  • 7.3 RESPIRATORY DISEASES
    RISE IN URBANIZATION, AIR POLLUTION, AND SMOKING TO FUEL RESPIRATORY AILMENTS
  • 7.4 OPTHALMOLOGY
    RISE OF DIABETIC EYE DISEASES AND FAVORABLE REGULATORY SCENARIO TO AUGMENT MARKET GROWTH
  • 7.5 AUTOIMMUNE DISEASES
    NEED FOR PROLONGED TREATMENT IN CHRONIC PATIENTS TO SPUR MARKET GROWTH
  • 7.6 ONCOLOGY
    DRUG DEVICE COMBINATION PRODUCTS TO AID THERAPEUTIC PRECISION AND OPTIMIZE PATIENT OUTCOMES DURING CANCER TREATMENT
  • 7.7 INFECTIOUS DISEASES
    IRREGULARIZED URBANIZATION AND POOR SANITATION IN EMERGING ECONOMIES TO PROPEL MARKET GROWTH
  • 7.8 CARDIOVASCULAR DISEASES
    INCREASE IN SEDENTARY LIFESTYLE AND CHANGES IN EATING HABITS TO FUEL MARKET GROWTH
  • 7.9 OBESITY MANAGEMENT
    INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH
  • 7.10 PAIN MANAGEMENT
    BETTER PATIENT ADHERENCE AND MINIMAL SIDE EFFECTS TO DRIVE ADOPTION OF TRANSDERMAL PATCHES
  • 7.11 OTHER APPLICATIONS
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER
152
  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS & CLINICS
    ACCESS TO MULTI-DISCIPLINARY EXPERTISE AND PROCEDURE-BASED CARE TO AID MARKET GROWTH
  • 8.3 AMBULATORY SURGERY CENTERS
    NEED FOR COST-EFFECTIVE AND HIGH-QUALITY MINIMALLY INVASIVE TREATMENT TO SUPPORT MARKET GROWTH
  • 8.4 LONG-TERM CARE FACILITIES
    INCREASING INCIDENCE OF CHRONIC DISEASES AMONG ELDERLY AND DISABLED POPULATION TO DRIVE MARKET
  • 8.5 HOME CARE SETTINGS
    INCREASING DEMAND FOR PATIENT-CENTRIC AND COST-EFFECTIVE HEALTHCARE TO PROPEL MARKET GROWTH
  • 8.6 OTHER END USERS
DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION
163
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US to dominate North American drug device combination products market during forecast period
    CANADA
    - Regulatory modernization and strategic government investments to augment market growth
  • 9.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Technological advancements and strong R&D infrastructure to propel market growth
    UK
    - Strong emphasis on personalized and value-based healthcare to aid market growth
    FRANCE
    - Strong healthcare infrastructure and high investments in biopharmaceutical innovation to boost market growth
    ITALY
    - Focus on pharmaceutical-meditech convergence and healthcare modernization to drive market
    SPAIN
    - Increasing geriatric population and growing focus on home-based treatment to propel market growth
    REST OF EUROPE
  • 9.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Favorable government policies and increased healthcare spending to support market growth
    JAPAN
    - Advanced healthcare systems and universal reimbursement policies to spur market growth
    INDIA
    - Growing focus on digital health integration and booming biosimilars sector to drive market
    SOUTH KOREA
    - Robust R&D infrastructure and enhanced focus on government-industry collaborations to aid market growth
    AUSTRALIA
    - Rising healthcare investments by government and private organizations to boost market growth
    REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Presence of universal healthcare system and high geriatric population to drive market
    MEXICO
    - Focus on nearshoring and improvement in healthcare sector to drive market
    REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Kingdom of Saudi Arabia
    - UAE
    - Rest of GCC countries
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
242
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET
  • 10.3 REVENUE ANALYSIS, 2020–2024
  • 10.4 MARKET SHARE ANALYSIS, 2024
    RANKING OF KEY MARKET PLAYERS
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Product type footprint
    - Application footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SME players
    - Competitive benchmarking of key startups/SME players
  • 10.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
266
  • 11.1 KEY PLAYERS
    ABBOTT
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ELI LILLY AND COMPANY
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    MEDTRONIC
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    NOVO NORDISK A/S
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    NOVARTIS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SANOFI
    - Business overview
    - Products offered
    - Recent developments
    BOSTON SCIENTIFIC CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products offered
    - Recent developments
    MERCK KGAA
    - Business overview
    - Products offered
    - Recent developments
    ABBVIE INC.
    - Business overview
    - Products offered
    - Recent developments
    TEVA PHARMACEUTICAL INDUSTRIES LTD.
    - Business overview
    - Products offered
    - Recent developments
    STRYKER
    - Business overview
    - Products offered
    B. BRAUN SE
    - Business overview
    - Products offered
    TERUMO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
  • 11.2 OTHER PLAYERS
    TANDEM DIABETES CARE, INC.
    CEQUR SIMPLICITY
    INTARCIA THERAPEUTICS, INC.
    HALOZYME, INC.
    KALEO, INC.
    LEAD CHEMICAL CO., LTD.
    PURDUE PHARMA L.P.
    ALVOGEN
    EVOLUTIS
    MUNDIPHARMA INTERNATIONAL LIMITED
    SPARSHA PHARMA INTERNATIONAL PVT. LTD.
    SUPERNUS PHARMACEUTICALS, INC.
    ALCON INC.
APPENDIX
335
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 DRUG DEVICE COMBINATION PRODUCTS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 3 DRUG DEVICE COMBINATION PRODUCTS MARKET: STUDY ASSUMPTIONS
  • TABLE 4 DRUG DEVICE COMBINATION PRODUCTS MARKET: RISK ANALYSIS
  • TABLE 5 DIABETES POPULATION WORLDWIDE, 2024 VS. 2050 (MILLION)
  • TABLE 6 DRUG DEVICE COMBINATION PRODUCTS MARKET: PORTER’S FIVE FORCES
  • TABLE 7 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS
  • TABLE 8 KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS
  • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 US: CLASSIFICATION AND APPROVAL PATHWAYS
  • TABLE 15 US: CLASSIFICATION OF MEDICAL EQUIPMENT
  • TABLE 16 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 17 CANADA: CLASSIFICATION OF DRUG DEVICE COMBINATION PRODUCTS
  • TABLE 18 CANADA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 19 EUROPE: EUROPEAN REGULATORY FRAMEWORK FOR DRUG DEVICE COMBINATION PRODUCTS
  • TABLE 20 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 21 CHINA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 22 JAPAN: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PATENTS GRANTED, JANUARY 2022−APRIL 2025
  • TABLE 24 IMPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 25 EXPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 26 IMPORTS DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 27 EXPORT DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 28 INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024
  • TABLE 29 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DEVICE DELIVERY DEVICES, BY KEY PLAYER, 2022–2024
  • TABLE 30 AVERAGE SELLING PRICE TREND FOR PEN INJECTORS, BY REGION, 2022–2024
  • TABLE 31 AVERAGE SELLING PRICE TREND FOR INHALERS, BY REGION, 2022–2024
  • TABLE 32 AVERAGE SELLING PRICE TREND FOR DRUG-ELUTING STENTS, BY REGION, 2022–2024
  • TABLE 33 DRUG DEVICE COMBINATION PRODUCTS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
  • TABLE 34 DRUG DEVICE COMBINATION PRODUCTS MARKET: ROLE IN ECOSYSTEM
  • TABLE 35 CASE STUDY 1: MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY
  • TABLE 36 CASE STUDY 2: DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION
  • TABLE 37 CASE STUDY 3: ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES
  • TABLE 38 DRUG DEVICE COMBINATION PRODUCTS MARKET: REIMBURSEMENT SCENARIO ANALYSIS
  • TABLE 39 DRUG DEVICE COMBINATION PRODUCTS MARKET: CLINICAL PIPELINE ANALYSIS (AS OF MARCH 2025)
  • TABLE 40 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 41 KEY PRODUCT-RELATED TARIFF FOR DRUG DEVICE PRODUCTS
  • TABLE 42 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 43 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 44 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 45 LIST OF KEY PREFILLED SYRINGES AVAILABLE IN MARKET
  • TABLE 46 PREFILLED SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 47 LAUNCH OF KEY GLP-1-RELATED INJECTABLES BY MAJOR PHARMACEUTICAL COMPANIES, 2010–2024
  • TABLE 48 LIST OF KEY PEN INJECTORS AVAILABLE IN MARKET
  • TABLE 49 PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 50 LIST OF KEY AUTOINJECTORS AVAILABLE IN MARKET
  • TABLE 51 AUTOINJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION)
  • TABLE 52 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045 (MILLION)
  • TABLE 53 LIST OF KEY WEREABLE INJECTORS AVAILABLE IN MARKET
  • TABLE 54 WEARABLE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 55 LIST OF KEY NEEDLE-FREE INJECTORS AVAILABLE IN MARKET
  • TABLE 56 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION)
  • TABLE 57 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-ELUTING STENTS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 58 LIST OF KEY INHALERS AVAILABLE IN MARKET
  • TABLE 59 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INHALERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 60 LIST OF KEY INFUSION PUMPS AVAILABLE IN MARKET
  • TABLE 61 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFUSION PUMPS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 62 LIST OF KEY TRANSDERMAL PATCHES AVAILABLE IN MARKET
  • TABLE 63 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 64 LIST OF KEY DRUG-COATED BALLOONS AVAILABLE IN MARKET
  • TABLE 65 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-COATED BALLOONS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 66 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER PRODUCT TYPES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 67 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 68 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DIABETES MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 69 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 70 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 71 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 72 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 73 KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR INFECTIOUS DISEASES
  • TABLE 74 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 75 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 76 KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR OBESITY MANAGEMENT
  • TABLE 77 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OBESITY MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 78 KEY TRANSDERMAL PATCHES AVAILABLE FOR PAIN MANAGEMENT
  • TABLE 79 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 80 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 81 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 82 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 83 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 84 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 85 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 86 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 87 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 88 TRANSDERMAL PATCHES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
  • TABLE 89 DRUG-ELUTING STENTS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
  • TABLE 90 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 91 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 92 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 93 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 94 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 95 US: KEY MACROINDICATORS
  • TABLE 96 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 97 US: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 98 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 99 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 100 CANADA: KEY MACROINDICATORS
  • TABLE 101 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 102 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 103 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 104 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 105 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 106 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 107 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 108 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 109 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 110 GERMANY: KEY MACROINDICATORS
  • TABLE 111 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 112 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 113 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 114 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 115 UK: KEY MACROINDICATORS
  • TABLE 116 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 117 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 118 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 119 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 120 FRANCE: KEY MACROINDICATORS
  • TABLE 121 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 122 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 123 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 124 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 125 ITALY: KEY MACROINDICATORS
  • TABLE 126 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 127 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 128 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 129 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 130 SPAIN: KEY MACROINDICATORS
  • TABLE 131 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 132 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 133 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 134 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 135 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 136 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 137 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 138 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 139 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 140 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 141 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 142 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 143 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 144 CHINA: KEY MACROINDICATORS
  • TABLE 145 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 146 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 147 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 148 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 149 JAPAN: KEY MACROINDICATORS
  • TABLE 150 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 151 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 152 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 153 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 154 INDIA: KEY MACROINDICATORS
  • TABLE 155 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 156 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 157 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 158 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 159 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 160 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 161 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 162 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 163 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 164 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 165 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 166 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 167 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 168 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 169 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 170 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 171 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 172 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 173 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 174 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 175 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 176 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 177 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 178 BRAZIL: KEY MACROINDICATORS
  • TABLE 179 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 180 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 181 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 182 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 183 MEXICO: KEY MACROINDICATORS
  • TABLE 184 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 185 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 186 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 187 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 188 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 189 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 190 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 191 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 192 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 193 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 194 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 195 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 196 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 197 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 198 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 199 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 200 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 201 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 202 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 203 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 204 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 205 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 206 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 207 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 208 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 209 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 210 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 211 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 212 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 213 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 214 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION)
  • TABLE 215 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 216 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION)
  • TABLE 217 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 218 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET
  • TABLE 219 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOINJECTORS: DEGREE OF COMPETITION
  • TABLE 220 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PEN INJECTORS: DEGREE OF COMPETITION
  • TABLE 221 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES: DEGREE OF COMPETITION
  • TABLE 222 DRUG DEVICE COMBINATION PRODUCTS MARKET: REGION FOOTPRINT
  • TABLE 223 DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT TYPE FOOTPRINT
  • TABLE 224 DRUG DEVICE COMBINATION PRODUCTS MARKET: APPLICATION FOOTPRINT
  • TABLE 225 DRUG DEVICE COMBINATION PRODUCTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 226 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS
  • TABLE 227 DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 228 DRUG DEVICE COMBINATION PRODUCTS MARKET: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 229 DRUG DEVICE COMBINATION PRODUCTS MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 230 DRUG DEVICE COMBINATION PRODUCTS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 231 ABBOTT: COMPANY OVERVIEW
  • TABLE 232 ABBOTT: PRODUCTS OFFERED
  • TABLE 233 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 234 ABBOTT: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 235 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 236 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 237 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 238 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 239 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 240 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 241 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 242 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 243 MEDTRONIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 244 MEDTRONIC: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 245 NOVO NORDISK A/S: COMPANY OVERVIEW
  • TABLE 246 NOVO NORDISK A/S: PRODUCTS OFFERED
  • TABLE 247 NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 248 NOVO NORDISK A/S: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 249 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 250 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 251 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 252 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 253 NOVARTIS AG: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 254 NOVARTIS AG: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 255 SANOFI: COMPANY OVERVIEW
  • TABLE 256 SANOFI: PRODUCTS OFFERED
  • TABLE 257 SANOFI: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 258 SANOFI: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 259 SANOFI: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 260 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 261 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 262 BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 263 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 264 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 265 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 266 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 267 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 268 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 269 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 270 MERCK KGGA: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 271 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 272 ABBVIE INC.: PRODUCTS OFFERED
  • TABLE 273 ABBVIE INC: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 274 ABBVIE INC.: DEALS, JANUARY 2022–MARCH 2025
  • TABLE 275 ABBVIE INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
  • TABLE 276 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 277 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 278 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 279 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
  • TABLE 280 STRYKER: COMPANY OVERVIEW
  • TABLE 281 STRYKER: PRODUCTS OFFERED
  • TABLE 282 B. BRAUN SE: COMPANY OVERVIEW
  • TABLE 283 B. BRAUN SE: PRODUCTS OFFERED
  • TABLE 284 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 285 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 286 TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
  • TABLE 287 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW
  • TABLE 288 CEQUR SIMPLICITY: COMPANY OVERVIEW
  • TABLE 289 INTARCIA THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 290 HALOZYME, INC.: COMPANY OVERVIEW
  • TABLE 291 KALEO, INC.: COMPANY OVERVIEW
  • TABLE 292 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 293 PURDUE PHARMA L.P.: COMPANY OVERVIEW
  • TABLE 294 ALVOGEN: COMPANY OVERVIEW
  • TABLE 295 EVOLUTIS: COMPANY OVERVIEW
  • TABLE 296 MUNDIPHARMA INTERNATIONAL LIMITED: COMPANY OVERVIEW
  • TABLE 297 SPARSHA PHARMA INTERNATIONAL PVT. LTD.: COMPANY OVERVIEW
  • TABLE 298 SUPERNUS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 299 ALCON INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 DRUG DEVICE COMBINATION PRODUCTS MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE
  • FIGURE 2 DRUG DEVICE COMBINATION PRODUCTS MARKET: YEARS CONSIDERED
  • FIGURE 3 DRUG DEVICE COMBINATION PRODUCTS MARKET: RESEARCH DESIGN
  • FIGURE 4 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PRIMARY SOURCES
  • FIGURE 6 DRUG DEVICE COMBINATION PRODUCTS MARKET: INSIGHTS FROM PRIMARIES
  • FIGURE 7 DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARIES (BY COMPANY TYPE, DESIGNATION, AND REGION)
  • FIGURE 8 DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
  • FIGURE 9 DRUG DEVICE COMBINATION PRODUCTS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024)
  • FIGURE 10 PEN INJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
  • FIGURE 11 AUTOINJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
  • FIGURE 12 DRUG DEVICE COMBINATION PRODUCTS MARKET: TOP-DOWN APPROACH
  • FIGURE 13 DRUG DEVICE COMBINATION PRODUCTS MARKET: CAGR PROJECTIONS (SUPPLY SIDE)
  • FIGURE 14 DRUG DEVICE COMBINATION PRODUCTS MARKET: DATA TRIANGULATION
  • FIGURE 15 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD BILLION)
  • FIGURE 16 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2025 VS. 2030 (USD BILLION)
  • FIGURE 17 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION)
  • FIGURE 18 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
  • FIGURE 19 REGIONAL SNAPSHOT OF DRUG DEVICE COMBINATION PRODUCTS MARKET
  • FIGURE 20 INCREASING NUMBER OF REGULATORY APPROVALS AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • FIGURE 21 CHINA AND DIABETES MANAGEMENT SEGMENT COMMANDED LARGEST MARKET SHARE IN 2024
  • FIGURE 22 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
  • FIGURE 23 DRUG DEVICE COMBINATION PRODUCTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 DISABILITY-ADJUSTED LIFE YEARS FOR INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA, BY AGE (2023)
  • FIGURE 25 SHARE OF GLOBAL GERIATRIC POPULATION (ABOVE 60 YEARS), BY REGION, 2010 VS. 2015 VS. 2030 (PROJECTED)
  • FIGURE 26 DRUG DEVICE COMBINATION PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS
  • FIGURE 28 KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS
  • FIGURE 29 DRUG DEVICE COMBINATION PRODUCTS MARKET: PATENT PUBLICATION TRENDS AND TOP APPLICANT ANALYSIS (JANUARY 2014–APRIL 2025)
  • FIGURE 30 TOP PATENT APPLICANTS FOR DRUG DEVICE COMBINATION PRODUCTS, BY JURISDICTION (JANUARY 2014–APRIL 2025)
  • FIGURE 31 DRUG DEVICE COMBINATION PRODUCTS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 32 DRUG DEVICE COMBINATION PRODUCTS MARKET: ADJACENT MARKETS
  • FIGURE 33 DRUG DEVICE COMBINATION PRODUCTS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 34 DRUG DEVICE COMBINATION PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 35 DRUG DEVICE COMBINATION PRODUCTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 36 DRUG DEVICE COMBINATION PRODUCTS MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023
  • FIGURE 37 DRUG DEVICE COMBINATION PRODUCTS MARKET: IMPACT OF AI/GEN AI
  • FIGURE 38 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT
  • FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET (2020–2024)
  • FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET (2024)
  • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEN INJECTORS MARKET (2024)
  • FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN TRANSDERMAL PATCHES MARKET (2024)
  • FIGURE 44 RANKING OF KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET (2024)
  • FIGURE 45 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 46 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY FOOTPRINT
  • FIGURE 47 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 48 EV/EBITDA OF KEY VENDORS
  • FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 50 DRUG DEVICE COMBINATION PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 51 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 53 MEDTRONIC: COMPANY SNAPSHOT
  • FIGURE 54 NOVO NORDISK A/S: COMPANY SNAPSHOT
  • FIGURE 55 NOVARTIS AG: COMPANY SNAPSHOT
  • FIGURE 56 SANOFI: COMPANY SNAPSHOT
  • FIGURE 57 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 58 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 60 ABBVIE INC.: COMPANY SNAPSHOT
  • FIGURE 61 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • FIGURE 62 STRYKER: COMPANY SNAPSHOT
  • FIGURE 63 B. BRAUN SE: COMPANY SNAPSHOT
  • FIGURE 64 TERUMO CORPORATION: COMPANY SNAPSHOT

 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies, and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), European Federation of Pharmaceutical Industries and Associations (EFPIA), American Journal of Drug Delivery and Therapeutics, International Diabetes Federation (IDF), American Association of Diabetes Educators (AADE), Asian Association for the Study of Diabetes (AASD) and Parenteral Drug Association (PDA) were referred to identify and collect information for the global drug device combination products market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends, to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the drug device combination products market. The primary sources from the demand side include hospitals & clinics and home care settings. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Drug Device Combination Products Market

*C-levels include CEOs, CFOs, COOs, and VPs.

*Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global drug device combination products market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 70–75% of the market share at the global level). Also, the global drug device combination products market was split into various segments and sub-segments based on:

  • List of major players operating in the drug device combination products market at the regional and/or country level
  • Product mapping of various drug device combination product manufacturers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from drug device combination products (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least 70–75% of the global market share as of 2024
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global point-of-care  diagnostics market  

Market Size Estimation (Bottom-up approach and Top-down approach)

Drug Device Combination Products Market

Data Triangulation

After arriving at the overall size of the global drug device combination products market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Market Definition

A combination product is defined as any amalgamation of a drug and a device, a biological product and a device, a drug and a biological product, or a triad comprising a drug, device, and biological product. This category encompasses products that consist of two or more regulated entities—such as drug/device, biologic/device, drug/biologic, or drug/device/biologic—that are integrated or formulated as a single entity through various physical, chemical, or other methodologies. Moreover, combination products may also refer to distinct components that are packaged either as a single unit or as a collaborative assembly of biological and drug compounds, device-to-device pairings, or drug and device integrations.

Stakeholders

  • Drug device combination products manufacturers and distributors
  • Healthcare institutions (hospitals, medical schools, and outpatient clinics)
  • Research institutes
  • Contract manufacturing organizations (CMOs)
  • Market research and consulting firms
  • Venture capitalists and investors
  • Market research and consulting firms
  • Government Bodies/Municipal Corporations
  • Regulatory Bodies
  • Medical Research Institutes
  • Business Research and Consulting Service Providers

Report Objectives

  • To define, measure, and describe the global drug device combination products market by product type, application, end user, and region
  • To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
  • To strategically analyze the regulatory analysis, pricing analysis, value chain analysis, supply chain analysis, ecosystem analysis, technology analysis, Porter’s Five Forces analysis, and patent analysis
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically analyze the market structure, profile the key players in the global drug device combination products market, and comprehensively analyze their core competencies
  • To track and analyze company developments such as acquisitions, partnerships, expansions, and product launches and approvals in the drug device combination products market
  • To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global drug device combination products  market

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.

By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Drug Device Combination Products Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2025 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status